QurAlis chief scientific officer Dan Elbaum (center) works with researchers in the ALS biotech’s Cambridge, MA lab.

ALS biotech QurAlis gets $88M boost from four phar­mas for pair of PhI stud­ies

QurAlis picked up $88 mil­lion for two Phase I stud­ies, hop­ing to ride reg­u­la­to­ry waves dri­ven by the re­cent FDA ap­proval of Amy­lyx Phar­ma­ceu­ti­cals’ ALS ther­a­py.

Four bio­phar­mas — Eli Lil­ly, Am­gen, Sanofi and Mit­subishi Tan­abe’s VC arm — are bankrolling a Se­ries B for the biotech from Har­vard stem cell pi­o­neers Kevin Eggan and Clif­ford Woolf. In De­cem­ber, the start­up be­gan in-hu­man tri­als of two ther­a­peu­tics for pa­tients with cer­tain types of the pro­gres­sive mus­cle weak­ness dis­ease, which comes with a short life ex­pectan­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.